Results 81 to 90 of about 42,597 (192)
DNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF
DNTTIP1 cooperates with SP1 to recruit HDAC1/2, leading to BMF silencing and reduced competitive binding of BMF to BCL2.This suppresses autophagy and apoptosis, promoting leukaemic cell survival. Targeting the DNTTIP1‐HDAC1/2‐BMF axis reactivates BMF and induces anti‐leukaemic effects.
Ruolin Xiu +12 more
wiley +1 more source
MicroRNAs in B cell development and malignancy [PDF]
MicroRNAs are small RNA molecules that regulate gene expression and play critical roles in B cell development and malignancy. miRNA expression is important globally, as B cell specific knockouts of Dicer show profound defects in B cell development; and ...
Fernando, Thilini R. +2 more
core +4 more sources
ABSTRACT Background The European ALLTogether protocol for childhood acute lymphoblastic leukemia, initiated in Sweden 2019, introduced earlier asparaginase during induction, dexamethasone instead of prednisone for all patients, and omitted anthracyclines from low‐risk induction to reduce treatment‐related toxicity.
Johannes Fermér +11 more
wiley +1 more source
Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia. [PDF]
High hyperdiploidy (HD), the most common cytogenetic subtype of B-cell acute lymphoblastic leukemia (B-ALL), is largely curable but significant treatment-related morbidity warrants investigating the biology and identifying novel drug targets.
de Smith, Adam J +10 more
core +1 more source
Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth +2 more
wiley +1 more source
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
Tisagenlecleucel is a CD19-specific chimeric antigen receptor (CAR)-T cell therapy approved for patients aged ≤25 years with relapsed or refractory B cell precursor acute lymphoblastic leukemia (B-ALL) and adults with relapsed or refractory diffuse large
Seshu Tyagarajan +2 more
doaj +1 more source
The model shows the probiotics screening and underlying mechanisms of F. rodentiumn in alleviating IR‐induced tissue injury. Stress‐induced STAT3 mitochondria localization decreases F. rodentium abundance and butyrate concentration. Supplementation of F.
Hanyong Zhu +17 more
wiley +1 more source
Acute myeloid leukemia (AML) remains a therapeutic challenge due to its heterogeneity and limited targets. Here, multi‐omics analyses are utilized, and it is revealed that AML cells, particularly the FLT3‐ITD+ subtype, undergo chaperone‐mediated ER stress, inducing surface translocation of ER chaperones.
Yimin Zhou +13 more
wiley +1 more source
Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells [PDF]
The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We
Aicher, A +9 more
core
CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol [PDF]
DNA copy number analysis has been instrumental for the identification of genetic alterations in B-cell precursor acute lymphoblastic leukemia. Notably, some of these genetic defects have been associated with poor treatment outcome and might be relevant ...
Bakkus, Marleen +27 more
core +3 more sources

